Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bortezomib + Dexamethasone + Ulocuplumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Ulocuplumab||BMS-936564|MDX1338||CXCR4 Inhibitor 15||Ulocuplumab (BMS-936564) is a monoclonal antibody that binds to CXCR4 and prevents binding of SDF-1 (CXCL12), potentially resulting in increased apoptosis and decreased migration of tumor cells (PMID: 23213054, PMID: 31672767).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Bortezomib + Dexamethasone + Ulocuplumab||Phase I||Actionable||In a Phase I trial, Ulocuplumab (BMS-936564) in combination with Velcade (bortezomib) and Adexone (dexamethasone) demonstrated safety and preliminary efficacy, resulted in an overall response rate of 25.0% (4/16) and a clinical benefit rate of 50% (8/16) in patients with relapsed multiple myeloma (PMID: 31672767).||31672767|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02666209||Phase I||Bortezomib + Dexamethasone + Ulocuplumab Dexamethasone + Lenalidomide + Ulocuplumab||Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma||No longer available|